Abstract
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer, occurring in <1% of all lung tumors. PSC is highly resistant to conventional cytotoxic chemotherapies and confers a poor prognosis. Two single-arm, multicenter phase-II trials were conducted to evaluate the efficacy and safety of PD-1 inhibitors in patients with PSC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
